Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose recombinant human interleukin-2 add-on therapy in depression (IL2REG)
2019-001696-36Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of aldesleukin in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Percentage Treg fold increase at Day 5 compared to baseline. Started May 2021; status: completed.
02
Drugs
aldesleukin
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2019-001696-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001696-36.